Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines: Basel Saturday, October 26, 2024, 14:00 Hrs [IST] This month, the NCCN ...
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...
A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...
Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...
University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...
A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...
Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...
As a health and medical reporter, I've covered a steady drumbeat of headlines about the alarming uptick in breast cancer cases among adults in their 20s, 30s and 40s. I've read the studies.
When Jamie LaScala turned 40 in 2015, she didn't think she needed a mammogram just yet, but a friend encouraged her to go. “I was right on the cusp of when you’re supposed to start getting the ...
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...
Breast cancer rates rose by 1 percent per year from 2012-2021 for all U.S. women combined, with steeper increases for women under 50 and Asian American and Pacific Islander women, according to the ...
This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback